Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

PARP Inhibition Improves PFS as Frontline Maintenance in Ovarian Cancer, OS Data Awaited

August 20th 2019

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

PARP Inhibition Continues to Make Waves in Ovarian Cancer

August 19th 2019

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Olaparib Plus Bevacizumab Improves PFS as Frontline Maintenance in Ovarian Cancer

August 14th 2019

Combining olaparib with standard bevacizumab significantly improved progression-free survival compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.

Expert Explains Intricacies of Molecular Testing in Ovarian Cancer

August 13th 2019

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

Neoadjuvant Chemo Shows Comparable Data to Upfront Surgery in Ovarian Cancer

August 8th 2019

Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.

Harnessing Immune Response in Advanced Ovarian Cancer

August 5th 2019

Mian M. Shahzad, MD, PhD, discusses the use of checkpoint inhibition in advanced ovarian cancer.

Assessing Strategies and Challenges in Newly Diagnosed and Recurrent Ovarian Cancer

August 5th 2019

Jeannie Chern, MD, discusses developments with genetic testing in ovarian cancer and key trials in patients with recurrent disease.

Is Neoadjuvant Chemo Becoming Standard of Care for Advanced Ovarian Cancer?

August 2nd 2019

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer

August 1st 2019

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

The Future of Managing Gynecologic Cancer

July 30th 2019

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

PARP Inhibitor Mechanisms of Resistance

July 30th 2019

PARP Inhibitor Toxicity Management

July 30th 2019

Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

PARP Inhibitor Trial Updates

July 30th 2019

Treatment Options for Patients with BRCA1/2

July 30th 2019